Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDUNN trial of MC0518 versus best available therapy for steroid-refractory acute graft-versus-host disease
2023-505737-26-00Phase 3Authorised
- Sponsor
- medac GmbH
- Start
- Mar 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of mesenchymal stromal cells, ex vivo cultured in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by medac GmbH. Primary endpoints: Overall response at Day 28 and Overall survival to Month 24. Planned start Mar 2024; status: authorised.
02
Drugs
mesenchymal stromal cells, ex vivo cultured
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2023-505737-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505737-26-00.